<DOC>
	<DOCNO>NCT03082768</DOCNO>
	<brief_summary>The overall goal protocol evaluate [ 18F ] MNI-968 ( aka PF-06730110 ) D1 receptor target radiopharmaceutical .</brief_summary>
	<brief_title>Phase 0 Study 18FMNI-968 Marker D1 Receptor Healthy Subjects</brief_title>
	<detailed_description>The overall goal protocol evaluate [ 18F ] MNI-968 ( aka PF-06730110 ) D1 receptor target radiopharmaceutical . - To measure dynamic uptake washout [ 18F ] MNI-968 brain use positron emission tomography ( PET ) healthy volunteer . - To measure blood metabolite [ 18F ] MNI-968 healthy volunteer perform invasive well non-invasive model ass [ 18F ] MNI-968 binding D1 receptor . - To acquire safety data follow injection [ 18F ] MNI-968 - Evaluation [ 18F ] MNI-968 PET reliability ( test/retest ) several outcome measure</detailed_description>
	<criteria>Are male female &gt; 18 year age &lt; 50 year age ; Are good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . Are able communicate well investigator , understand comply requirement study , understand sign write informed consent . Female subject must document medical record physician 's note either surgically sterile ( mean hysterectomy , bilateral oophorectomy , tubal ligation ) postmenopausal least 1 year , childbearing potential , must commit use barrier contraception method duration study . Male subject partner childbearing potential must commit use two method contraception , one barrier method male subject study duration . Male subject must donate sperm study duration . Provide inform consent study procedure . Use prescription drug , herbal supplement , within four ( 4 ) week prior initial dosing , and/or overthecounter ( OTC ) medication , dietary supplement ( vitamin include ) within two ( 2 ) week prior initial dosing . If need ( i.e . incidental limit need ) , acetaminophen acceptable , must document concomitant medication / significant nondrug therapy . Subject receive investigational therapeutic drug device within 30 day screen Prior participation research protocols clinical care last year addition radiation exposure expect participation clinical study , radiation exposure exceed effective dose 50 mSv , would acceptable annual limit establish US Federal Guidelines Have history blood donation excess 500 mL blood within 30 day prior screen . Have history presence significant cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological disorder , opinion investigator , capable alter absorption , metabolism , elimination drug pose health risk participate study . Have clinically significant finding laboratory evaluation . Have clinically significant finding ECG evaluation base cardiology review . History immunodeficiency disease , include positive HIV test result . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody test result . History drug alcohol abuse within 12 month prior screen , evidence abuse indicate laboratory assay conduct screen . History tobacco product use within 3 month prior screen , verified urine cotinine screening . Positive pregnancy test result use serum betaHCG , female . Women lactate breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HV</keyword>
</DOC>